SUPN240816C34000
- 1.70
- 0.000.00%
Supernus Pharmaceuticals Newsroom
Strong Week for Supernus Pharmaceuticals (NASDAQ:SUPN) Shareholders Doesn't Alleviate Pain of Five-year Loss
The main aim of stock picking is to find the market-beating stocks. But every investor is virtually certain to have both over-performing and under-performing stocks. So we wouldn't blame long term S
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
ROCKVILLE, Md., May 30, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
TD Cowen Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $43
TD Cowen analyst Stacy Ku maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $43.According to TipRanks data, the analyst has a success rate of 23.8% and
Piper Sandler Maintains Supernus Pharmaceuticals(SUPN.US) With Buy Rating, Maintains Target Price $41
Piper Sandler analyst David Amsellem maintains $Supernus Pharmaceuticals(SUPN.US)$ with a buy rating, and maintains the target price at $41.According to TipRanks data, the analyst has a success rate o
Stifel Maintains Supernus Pharmaceuticals(SUPN.US) With Hold Rating, Maintains Target Price $38
Stifel analyst Annabel Samimy maintains $Supernus Pharmaceuticals(SUPN.US)$ with a hold rating, and maintains the target price at $38.According to TipRanks data, the analyst has a success rate of 45.5
Piper Sandler Sticks to Its Buy Rating for Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Reports 'Clinical Utility' From Epilepsy Treatment Study
Supernus Pharmaceuticals (SUPN) said data from an interim analysis of a phase 2a study of SPN-817 demonstrated "strong evidence" of clinical utility in epilepsy. The study is examining the safety and
Express News | Supernus Pharmaceuticals Announces Interim Analysis Data From Phase 2a Clinical Study Of SPN-817 For Treatment-Resistant Seizures
Express News | Supernus Pharmaceuticals Inc: Spn-817 Discontinuation Rate Due to Adverse Events (AES) of 22% in Titration Period and 2.4% in Maintenance Period
Express News | Supernus Pharmaceuticals Inc: Spn-817 Was Safe and Had Acceptable Tolerability
Express News | Supernus Announces Promising Interim Data From Ongoing Open-Label Phase 2a Study of Spn-817 in Epilepsy
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
Supernus Pharmaceuticals First Quarter 2024 Earnings: EPS: US$0.002 (Vs US$0.31 in 1Q 2023)
Supernus Pharmaceuticals to Host Webcast to Review Interim Data From Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
Piper Sandler Remains a Buy on Supernus Pharmaceuticals (SUPN)
Supernus Pharmaceuticals Reiterates FY24 Revenue $580M-$620M Vs $601.461M Est.
Supernus Pharmaceuticals Reiterates FY24 Revenue $580M-$620M Vs $601.461M Est.
Express News | Supernus Pharmaceuticals Reiterates FY24 Revenue $580M-$620M Vs $601.461M Est
Express News | Supernus Pharmaceuticals Q1 Sales $143.600M Miss $145.832M Estimate
Supernus Pharmaceuticals Reports Mixed Q1 Results; Reaffirms FY24 Outlook